BARACLUDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Baraclude, and when can generic versions of Baraclude launch?
Baraclude is a drug marketed by Bristol Myers Squibb and is included in two NDAs.
The generic ingredient in BARACLUDE is entecavir. There are eighteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the entecavir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Baraclude
A generic version of BARACLUDE was approved as entecavir by HETERO LABS LTD V on August 21st, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BARACLUDE?
- What are the global sales for BARACLUDE?
- What is Average Wholesale Price for BARACLUDE?
Summary for BARACLUDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 112 |
Clinical Trials: | 69 |
Patent Applications: | 5,320 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BARACLUDE |
What excipients (inactive ingredients) are in BARACLUDE? | BARACLUDE excipients list |
DailyMed Link: | BARACLUDE at DailyMed |
![BARACLUDE drug patent expirations Drug patent expirations by year for BARACLUDE](/p/graph/s/t/BARACLUDE-patent-expirations.png)
![Drug Prices for BARACLUDE](/p/graph/drug-price/BARACLUDE.png)
Recent Clinical Trials for BARACLUDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shanghai Zhimeng Biopharma, Inc. | Phase 2 |
Tigermed Consulting Co., Ltd | Phase 2 |
Ascentage Pharma Group Inc. | Phase 2 |
Pharmacology for BARACLUDE
Drug Class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
US Patents and Regulatory Information for BARACLUDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | BARACLUDE | entecavir | SOLUTION;ORAL | 021798-001 | Mar 29, 2005 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol Myers Squibb | BARACLUDE | entecavir | TABLET;ORAL | 021797-001 | Mar 29, 2005 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bristol Myers Squibb | BARACLUDE | entecavir | TABLET;ORAL | 021797-002 | Mar 29, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BARACLUDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | BARACLUDE | entecavir | SOLUTION;ORAL | 021798-001 | Mar 29, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | BARACLUDE | entecavir | TABLET;ORAL | 021797-001 | Mar 29, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | BARACLUDE | entecavir | SOLUTION;ORAL | 021798-001 | Mar 29, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | BARACLUDE | entecavir | TABLET;ORAL | 021797-002 | Mar 29, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for BARACLUDE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Mylan Pharmaceuticals Limited | Entecavir Mylan | entecavir | EMEA/H/C/004377 Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to |
Authorised | yes | no | no | 2017-09-18 | |
Bristol-Myers Squibb Pharma EEIG | Baraclude | entecavir | EMEA/H/C/000623 Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis;decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B. |
Authorised | no | no | no | 2006-06-26 | |
Accord Healthcare S.L.U. | Entecavir Accord | entecavir | EMEA/H/C/004458 Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:, , , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis., decompensated liver disease., , , For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B., , Entecavir Accord is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to |
Authorised | yes | no | no | 2017-09-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for BARACLUDE
See the table below for patents covering BARACLUDE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Netherlands | 300241 | ⤷ Sign Up | |
Hong Kong | 1001343 | ⤷ Sign Up | |
Israel | 99755 | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines and pharmaceutical compositions containing the same | ⤷ Sign Up |
Poland | 292101 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 9704753 | ⤷ Sign Up | |
Austria | 401062 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BARACLUDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0481754 | C00481754/01 | Switzerland | ⤷ Sign Up | FORMER OWNER: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH |
0481754 | 06C0040 | France | ⤷ Sign Up | PRODUCT NAME: ENTECAVIR; REGISTRATION NO/DATE: EU/1/06/343/001 20060626 |
0481754 | 91275 | Luxembourg | ⤷ Sign Up | CERTIFICATE TITLE: ENTECAVIR ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BARACLUDE); FIRST REGISTRATION: 20060626 |
0481754 | 33/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: ENTECAVIR UND DESSEN HYDRATE; REGISTRATION NO/DATE: EU/1/06/343/001- EU/1/06/343/005 20060626 |
0481754 | C300241 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ENTECAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT, IN HET BIJZONDER ENTECAVIRMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/06/343/001-EU/1/06/343/005 20060626 |
0481754 | CA 2006 00033 | Denmark | ⤷ Sign Up | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |